UF scientists work to develop simple bladder cancer test

July 05, 2007

GAINESVILLE, Fla. -- University of Florida researchers have identified a set of proteins that appear to signal the presence of bladder cancer, a discovery they hope will lead to a simple, fast and noninvasive test that can detect the disease early.

Working with colleagues at the University of Michigan, the scientists used advances in technology to isolate nearly 200 proteins from the urine of patients with and without bladder cancer. Several appear promising as potential biomarkers, including one that studies conducted elsewhere have already linked to liver and ovarian cancer. The findings, available online, are scheduled to be published in the July 6 print edition of the American Chemical Society's Journal of Proteome Research.

Developing a simple "dipstick" test that would better single out patients whose symptoms are linked to cancer would enable those who simply have an infection to avoid a battery of screenings that typically include cystoscopy, a painful procedure that uses a small camera threaded through the urethra to image the bladder's interior. Such a test also could be used to detect cancer sooner, possibly before its signs even surface.

"With any cancer, the earlier you find it the better because it's not as aggressive in its early stages, and of course it's much easier to remove any cancer anywhere in the body if you catch it while it's relatively small," said Steve Goodison, an associate professor of surgery at the UF College of Medicine-Jacksonville.

"What would really help in this disease would be a test you could use to monitor these patients just by monitoring their urine," he added. "If we could develop this test to try to narrow down those who've got infections versus something more serious, that would relieve the patient from pain and worry and (cut health-care costs). The final aim would be to make a test cheap and convenient enough that you can start to think of screening people who don't have any symptoms."

Bladder cancer ranks among the five most common malignancies. The American Cancer Society estimates that in 2007 there will be about 67,160 new cases of bladder cancer diagnosed in the United States. Four times more men than women contract the disease, and smoking as well as exposure to industrial toxins increases the risk. Although the five-year survival rate is about 94 percent when it is detected early, bladder cancer is extremely difficult to cure because it tends to recur.

"Imagine the bladder like a balloon, and the tumors grow into the interior of the balloon," Goodison said. "So the surgeons go in and want to be as least disruptive as possible, so they nip these growths off from the inside, but unfortunately once it's happened it's very likely going to happen again -- once you have bladder cancer you are at a high risk of recurrence for the rest of your life, which makes monitoring it a real problem."

As a result patients need to be closely monitored, with most undergoing cystoscopy every few months in the first year after diagnosis and as frequently as every six months thereafter. Meanwhile, the urine tests currently used to detect recurrent bladder cancer miss 60 percent to 75 percent of all malignancies, especially those that are low-grade or early stage.

"They haven't proven to be accurate enough to make the urologists confident to use them instead of doing manual inspection to date (using cystoscopy)," Goodison said. "The trouble is, a lot of tests tend to look at only one biomarker, and one biomarker is never really going to do it, you need to do a panel. You need something like six biomarkers on a dipstick and if four of the six come up then you have an accurate answer. Tests that look at one protein are not going to do it because cancer is so different between individuals."

In the current study, scientists used a technique to search for glycoproteins -- a subset of proteins naturally secreted into the urine from the bladder lining -- in urine samples from 10 individuals, five of whom had bladder cancer. Each sample was small, on average about 30 milliliters, equivalent to a fluid ounce. In contrast, previous urine protein profiles required large-volume samples.

Of the 186 proteins identified in the study, five were present only in the patients with cancer. The findings also substantially add to the urinary proteome database, which until now only contained 146 proteins. Additional studies are planned to screen samples from a larger number of bladder cancer patients with a variety of disease stages and grades, Goodison said.

"Even though our study involved a small number of patients so far, this was really a proof of principle that we can use these new techniques to detect proteins in the urine," Goodison said. "Nobody could do that at this (degree of) sensitivity until now."

The study was funded through a grant from the Florida Department of Health. Goodison's collaborators included UF urologic surgeon Dr. Charles Rosser, and David Lubman, a protein chemist at the University of Michigan.

"The development of novel non-invasive methods for early detection of bladder cancer is very exciting and represents a major step in (making) routine screening of patients with urological disease feasible in the future," said Nicholas C. Popescu, chief of the molecular cytogenetics section at the National Cancer Institute's Laboratory of Experimental Carcinogenesis. "In addition, interactions among specific proteins could lead to the development of effective therapy of bladder cancer, a major cause of cancer death worldwide."
-end-


University of Florida

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.